An analysis of hot issues in immunotherapy for non-small cell lung cancer
10.13406/j.cnki.cyxb.003854
- VernacularTitle:非小细胞肺癌免疫治疗热点问题解析
- Author:
Zhimin ZHANG
1
;
Bicheng ZHANG
Author Information
1. 武汉大学人民医院肿瘤中心,武汉 430060
- Keywords:
non-small cell lung cancer;
immunotherapy;
analysis
- From:
Journal of Chongqing Medical University
2025;50(6):726-733
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy,represented by immune checkpoint inhibitors,has been widely used in patients with non-small cell lung cancer(NSCLC).With remarkable therapeutic efficacy,immunotherapy has been recommended by multiple domestic and international guidelines and expert consensuses.However,there are still some controversial clinical issues worth discussing in the current immuno-therapy of NSCLC,such as perioperative immunotherapy selection,immune resistance mechanisms and treatment strategies after drug resistance,the evaluation of immunotherapy efficacy,the management of adverse immune reactions,immunotherapy strategies for driver gene-positive patients,immunotherapy selection in special populations,and other immunotherapy-related clinical issues of con-cern.This article presents and discusses seven hot issues in NSCLC immunotherapy,aiming to provide a reference for tumor clinicians.
